Literature DB >> 22693200

Recombinant activated factor VII as treatment for uncontrolled mucosal haemorrhage.

J Gracia1, I Prieto.   

Abstract

We report the use of a haemostatic drug (recombinant activated factor VII (rFVIIa)) in a patient who presented a slow but constant bleed in oesophageal mucosa (which required frequent red blood cell transfusion) due to ingestion of caustic products. The administration of rFVIIa ceased bleeding and allowed mucosal cicatrisation and patient haemodynamic stabilisation and clinical recovery.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22693200      PMCID： PMC3128341          DOI： 10.1136/bcr.09.2009.2306

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  9 in total

Review 1.  Pharmacokinetics of recombinant activated factor VII (rFVIIa).

Authors:  E Erhardtsen
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

2.  Risk factors for stricture development after caustic ingestion.

Authors:  Amadeu C R Nunes; José M Romãozinho; José M Pontes; Vitor Rodrigues; Manuela Ferreira; Dário Gomes; Diniz Freitas
Journal:  Hepatogastroenterology       Date:  2002 Nov-Dec

Review 3.  Recombinant factor VIIa (Novoseven) as a hemostatic agent.

Authors:  U Hedner
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

Review 4.  Recombinant activated factor VII and the anaesthetist.

Authors:  I J Welsby; D M Monroe; J H Lawson; M Hoffmann
Journal:  Anaesthesia       Date:  2005-12       Impact factor: 6.955

Review 5.  Mechanism of action of factor VIIa in the treatment of coagulopathies.

Authors:  Ulla Hedner
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

Review 6.  Corrosive ingestion in adults.

Authors:  Kovil Ramasamy; Vivek V Gumaste
Journal:  J Clin Gastroenterol       Date:  2003-08       Impact factor: 3.062

Review 7.  Safety profile of recombinant factor VIIa.

Authors:  Harold R Roberts; Dougald M Monroe; Maureane Hoffman
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

Review 8.  Recombinant factor VIIa: its background, development and clinical use.

Authors:  Ulla Hedner
Journal:  Curr Opin Hematol       Date:  2007-05       Impact factor: 3.284

9.  Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.

Authors:  Jean-Louis Vincent; Rolf Rossaint; Bruno Riou; Yves Ozier; David Zideman; Donat R Spahn
Journal:  Crit Care       Date:  2006       Impact factor: 9.097
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.